Literature DB >> 18508981

Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms.

Y-x He1, Q-y Guo.   

Abstract

Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) has been widely used not only for detecting and staging malignant tumours but also for monitoring therapy response and for differentiating malignant lesions from benign lesions. However, the sensitivity of 18F-FDG PET for hepatocellular carcinoma (HCC) is low. Recent research about the novel drug shows that the sensitivity of 11C-acetate PET for HCC is higher than that of 18F-FDG PET and 11C-acetate also indicates tumour cell differentiation. 18F-FDG PET proved to be highly sensitive in detecting hepatic metastases from different primaries. 18F-FDG PET has also been shown to be useful and more accurate than conventional imaging modalities in demonstrating the effect of local treatments in liver tumours. With the development of small animal imaging, animal research about 18F-FDG PET is increasing.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18508981     DOI： 10.1136/pgmj.2007.066589

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  9 in total

Review 1.  The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.

Authors:  Oreste Bagni; Luca Filippi; Orazio Schillaci
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

2.  18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Authors:  Mario Jreige; Periklis Mitsakis; Axel Van Der Gucht; Anastasia Pomoni; Marina Silva-Monteiro; Silvano Gnesin; Ariane Boubaker; Marie Nicod-Lalonde; Rafael Duran; John O Prior; Alban Denys; Niklaus Schaefer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-23       Impact factor: 9.236

3.  Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma.

Authors:  Michele Basso; Maria Basso; Alessandro Iaculli; Maurizio Pompili; Laura Riccardi; Brunella Barbaro; Vittoria Rufini; Alessandra Cassano; Paola Castaldi; Carlo Barone
Journal:  Case Rep Oncol       Date:  2010-11-06

4.  PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions.

Authors:  Ser Yee Lee; T Peter Kingham; Maria D LaGratta; Jose Jessurun; Daniel Cherqui; William R Jarnagin; Michael D Kluger
Journal:  HPB (Oxford)       Date:  2015-12-11       Impact factor: 3.647

5.  Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis.

Authors:  Feng Xia; Lin Wu; Wan-Yee Lau; Guo Li; Hongbo Huan; Cheng Qian; Kuansheng Ma; Ping Bie
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

6.  A potential diagnostic role of dual-phase 18F-FDG PET/CT scanning.

Authors:  Clare Jones; Stephen Badger; Tom Lynch
Journal:  Ulster Med J       Date:  2014-01

7.  Dynamic chaotic gravitational search algorithm-based kinetic parameter estimation of hepatocellular carcinoma on 18F-FDG PET/CT.

Authors:  Jianfeng He; Tao Wang; Yongjin Li; Yinglei Deng; Shaobo Wang
Journal:  BMC Med Imaging       Date:  2022-02-06       Impact factor: 1.930

Review 8.  Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine.

Authors:  Liang Wang
Journal:  Hepat Med       Date:  2010-08-17

Review 9.  Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.

Authors:  Liqin Zhu; Zhikai Ding; Xingliang Li; Hongyuan Wei; Yue Chen
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.